Sigilon Therapeutics is a biopharmaceutical company that develops functional cures for patients with a range of chronic illnesses by using the human cell’s power through its Shielded Living Therapeutics™ platform.
Sigilon’s product candidates are non-viral engineered cell-based therapies that aim to create the necessary proteins, enzymes, or other therapeutic molecules for people with chronic illnesses such as lysosomal diseases and diabetes.
The engineered cells are encapsulated by Sigilon’s Afibromer™ biomaterials matrix, designed to reduce and shield them from immune rejection. Sigilon was founded by Flagship Pioneering in 2016 in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.
Treatments based on the Sigilon Therapeutics platform combine advanced cell engineering with cutting-edge innovations in biocompatible materials to pioneer a new class of therapeutics, Shielded Living Therapeutics™ (SLTx), that provide durable, controllable, and safe treatment for serious chronic diseases.
In April 2018, Sigilon and Eli Lilly announced a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes.
The company’s Shielded Living Therapeutics™ platform combines proprietary Afibromer™ technology with novel, engineered human cell lines that can produce a wide range of proteins aimed at treating serious chronic disorders.
Sigilon’s pipeline of products includes hemophilia, lysosomal storage diseases, and, in collaboration with Eli Lilly, type 1 diabetes.
Sigilon is currently carrying out preclinical studies in other chronic disease indications while the primary programs rapidly advance toward clinical use.
The company also believes it will find uses for Afibromer™ beyond cell therapy such as the potential to reduce the incidence of fibrosis when using glass, plastic, or metal in coronary stents and other medical implants.